Notice of Knight Therapeutics’ Fourth Quarter 2020 Results Conference Call
MONTREAL, March 18, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter 2020 financial results on Thursday, March 25, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ – New Innovative Treatment for Irritable Bowel Syndrome with Constipation
MONTREAL, March 01, 2021 — Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of […]
Knight Announces Filing of Final Base Shelf Prospectus
MONTREAL, Dec. 23, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“) today has filed and has obtained a receipt for a (final) short form base shelf prospectus (the “Shelf Prospectus“). The Shelf Prospectus was filed with the securities regulatory authorities in each of the provinces of Canada and enables Knight to offer for sale and […]
Knight Announces Filing of Preliminary Base Shelf Prospectus
MONTREAL, Dec. 10, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“) filed a preliminary short form base shelf prospectus with securities regulatory authorities in each of the provinces of Canada. Once a receipt for the final short form base shelf prospectus (“Shelf Prospectus“) has been obtained from applicable Canadian securities regulatory authorities, this will enable […]
Knight Therapeutics Reports Third Quarter 2020 Results
MONTREAL, Nov. 13, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2020. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q3 2020 […]
Notice of Knight Therapeutics’ Third Quarter 2020 Results Conference Call
MONTREAL, Nov. 06, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2020 financial results on Friday, November 13, 2020 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight Signs New Exclusive AmBisome® Agreement with Gilead in Brazil
MONTREAL, Oct. 26, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“), a leading pan-American (ex-US) specialty pharmaceutical company, today announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. (“Gilead“) for the commercialization of AmBisome® (liposomal amphotericin B) in Brazil. The agreement will be effective starting January 1, 2021. “We’re excited to […]
Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer
MONTREAL, Sept. 03, 2020 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada. NERLYNX was originally approved by Health Canada in July 2019 for the extended adjuvant treatment of women with early […]
Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
MONTREAL and BOCA RATON, Fla, Aug. 25, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, […]
Knight Therapeutics Completes the Tender Offer for Grupo Biotoscana And Achieves Over 95% Ownership
MONTREAL, Aug. 14, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“), a leading pan-American (ex-US) specialty pharmaceutical company, today announced the results of the tender offer process (“Tender Offer“) for the acquisition of all outstanding Brazilian Depositary Receipts (“BDRs“) of Biotoscana Investments S.A. (“GBT“). A total of 49,778,512 of BDRs were tendered by BDR holders […]
